Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Eli Lilly and Company, Indianapolis, IN , United States

Survival: 10.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Gemzar
Country: United States
City/State/Province: Indianapolis, IN
Hospital: Eli Lilly and Company
Journal: Link
Date: 5/2006

Patients: This Phase II trial involved a total of 53 patients with advanced non-small-cell lung cancer. There were 35 men and 18 women and the median age was 67. Twenty-seven patients had adenocarcinoma, 13 had squamous cell, 2 had large cell, and 11 were consider “unclassified/other.” Forty-five patients had stage IV and 8 patients had stage IIIB. None of the patients had received prior chemotherapy.

Treatment: The treatment consisted of chemotherapy (gemcitabine and pemetrexed). In addition, all patients received folic acid, vitamin B12, and steroid prophylaxis.

Toxicity: Grade 4 toxicities included hematologic, dyspnea, pyrexia, and pleural effusion.

Results: The median overall survival was 10.3 months.

Support: The study was supported by Eli Lilly and Company.

Correspondence: Joseph Treat, MD

E-mail to a Friend Email Physician More Information